Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology

Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., & Horwitz, S. M. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology, 41(S2), 499–500. Portico. https://doi.org/10.1002/hon.3164_367
Authors:
Neha Mehta‐Shah
E. D. Jacobsen
Pier Luigi Zinzani
Jasmine Zain
Monica Mead
C. Casulo
G. Gritti
Lauren Pinter‐Brown
Koji Izutsu
Simon Waters
Jonathan E. Brammer
Barbara Pro
Steven M. Horwitz
Affiliated Authors:
Barbara Pro
Columbia Affiliation:
Subjects:
Lymphoid Neoplasms (OpenAlex Topic)
Human T-cell Leukemia Virus Type 1 Infection (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1002/hon.3164_367
PMID:
39112191
DOI:
10.1002/hon.3164_367
Journal:
Hematological Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: